Integrated Center for Oncology

Breast Cancer Gene-Expression Miner v4.5
(bc-GenExMiner v4.5)

bc-GenExMiner logo


Gene correlation exhaustive analysis Tutorial

Enter input gene:

  • GENE EXPRESSION DATA Open
  • First, choose your gene expression data. Information about cohorts : microarrays, Affymetrix®, METABRIC, TCGA or SCAN-B (aka GSE81540 = GSE81538 + GSE96058)

    Then fill the textbox with actualised* gene symbol.

    *: see actualised web databases (e.g.: GeneCards, Ensembl, HGNC, NCBI Gene...)



  • DNA microarrays
  • (n = 10 001)
  • RNA-seq
  • (n = 4 712)

  • POPULATION Open
  • Choose one of the radio button to select which population you want to explore for patients.
    RIMSPC as Robust Intrinsic Molecular Subtype Predictors Classification based on patients classified in the same molecular subtype with the six classifications. More details about molecular subtypes here.

    This analysis is only available with Affymetrix™ data.
    This option allows you to split triple-negative breast cancer (TNBC) samples and explore their three subtypes: C1, C2 and C3:
    • C1: molecular apocrine tumours (or luminal androgen receptor);
    • C2: basal-like tumours infiltrated by immune suppressive cells and high neurogenesis activity;
    • C3: basal-like tumours triggering an ineffective immune response; which is associated with high tumour infiltrating lymphocytes and plasma cells; tertiary lymphoid structures and upregulation of immune checkpoints.
    More details about TNBC subtypes classification here.



    Legend Open

     IHC:immunohistochemistry
     PAM50:Parker's instrinsic molecular subtypes
     RIMSPC:Robust Intrinsic Molecular Subtype Predictors Classification based on patients classified in the same molecular subtype with the six classifications.
    More details about molecular subtypes here.
     TNBC:triple-negative breast cancer; tumours negative for oestrogen and progesterone receptors and growth factor receptor 2 (HER2), by means of IHC.


    © 2010 About us    Contact Last update June 22, 2020 Disclaimer Site map
    2020